Wilson Disease - Comprehensive Overview

What Is It?

Pathophysiology - What Goes Wrong

1. In the trans-Golgi: ATP7B loads copper into apoceruloplasmin → secreted as ceruloplasmin into blood
2. In lysosomes: ATP7B transfers excess copper to bile canaliculi → excreted in bile (the major copper excretion route)

• Copper accumulates in hepatocyte cytoplasm and lysosomes → increased ROS → hepatocyte injury
• Low ceruloplasmin is a hallmark, but the low ceruloplasmin itself does not cause the disease - it is a marker
• As the liver is overwhelmed, non-ceruloplasmin-bound copper spills into the bloodstream, causing:
  • Hemolysis (copper damages red cell membranes)
  • Copper deposition in brain (especially basal ganglia), corneas, kidneys, bones, joints, parathyroid glands
  • Markedly increased urinary copper excretion

Clinical Presentation - Who Gets It and When

Liver Manifestations

• Asymptomatic: Incidentally elevated transaminases (ALT/AST) - any patient under 50-60 with unexplained elevated liver enzymes should have WD excluded
• Acute hepatitis: Mimics viral or autoimmune hepatitis; steatohepatitis pattern; may show Mallory hyaline bodies
• Chronic hepatitis: Progresses to cirrhosis in advanced cases
• Acute liver failure (fulminant): Up to 12% of presentations; dramatic - occurs in adolescents/young adults; presents with rapid-onset jaundice, ascites, coagulopathy, hepatic coma, acute renal failure, and Coombs-negative (DAT-negative) hemolytic anemia. Uniformly fatal without liver transplant. Key lab clue: alkaline phosphatase/total bilirubin ratio <4 and AST/ALT ratio >2.2 distinguishes WD from other causes of acute liver failure.
• Cirrhosis: End-stage hepatic WD; may present with features of portal hypertension

Neurological Manifestations

• Tremor (sometimes "wing-beating" character)
• Chorea
• Dystonia
• Dysarthria and dysphagia
• Ataxia, gait disturbance
• Fixed "sardonic" smile
• Seizures (minority)

Neuropsychiatric Manifestations

• Personality/mood changes (most common)
• Depression (~30%)
• Bipolar spectrum symptoms (~20%)
• Suicidal ideation (5-15%)
• Irritability, aggression, psychosis
• Cognitive disturbance with frontosubcortical pattern
• Increased sensitivity to neuroleptics (important clinical note)
• Despite long-term treatment, ~70% of WD patients develop some psychiatric symptoms

Other Organ Involvement

• Eyes: Kayser-Fleischer (KF) rings - green-brown copper deposits in Descemet membrane at corneal limbus; present in 98% of patients with neurological disease and ~80% of all WD cases; requires slit-lamp examination; almost always present in neurological WD
• Kidneys: Renal tubular dysfunction (Fanconi syndrome) - leads to low serum uric acid (important clue), aminoaciduria, phosphaturia
• Bones/joints: Bone demineralization, rickets, spontaneous fractures, osteochondritis dissecans, degenerative arthritis
• Heart: Echocardiographic abnormalities in up to 1/3 of adults; arrhythmias; orthostatic hypotension
• Skin: Increased pigmentation (especially anterior lower legs)
• Endocrine: Various reported abnormalities; parathyroid copper deposition
• Blood: Coombs-negative hemolytic anemia (15% at initial presentation when copper poorly controlled)

Investigations and Diagnosis

Key Lab Tests

Relative Exchangeable Copper (REC)

Leipzig Diagnostic Scoring System

• Score ≥4: WD highly likely, treat
• Score 3: possible, further tests needed
• Score ≤2: WD unlikely

Treatment

"With effective lifelong chelation treatment, most patients live normal, healthy lives. Starting treatment early is critical, and the outcome is best for patients in whom the disease is diagnosed and treatment begun when the patient is asymptomatic."

• Sleisenger and Fordtran's GI and Liver Disease

1. D-Penicillamine (first-line chelator, historically)

• Dose: 1-1.5 g/day in adults (20 mg/kg/day in children), divided 2-3 doses; maintenance 0.75-1 g/day
• Always co-prescribe pyridoxine 25 mg/day (penicillamine is an anti-pyridoxine agent)
• Monitoring efficacy: Target 24-hr urinary copper 200-500 μg/day
• Mechanism: Chelates copper and greatly increases urinary excretion
• Side effects (significant, reason many centers now prefer trientine):
  • Skin: rashes, pemphigus, elastosis perforans serpiginosa
  • Renal: proteinuria, nephrotic syndrome, Goodpasture syndrome
  • Hematologic: leukopenia, thrombocytopenia, aplastic anemia (rare but may not reverse)
  • Autoimmune: SLE-like syndrome, myasthenia syndrome
  • Neurological worsening in 20-50% of patients with neurological WD - some do not recover to pretreatment baseline. This is a major concern.
  • Loss of taste, GI upset, arthralgias

2. Trientine (triethylenetetramine) - now preferred first-line at many centers

• Dose: 1-1.5 g/day (adults), divided 2-3 doses; maintenance 0.75-1.2 g/day
• Children: approximately 20 mg/kg/day (not well established)
• Monitoring: Same urinary copper targets as penicillamine
• Mechanism: Chelates copper via 4 constituent nitrogens in planar ring; increases urinary copper excretion; may also interfere with intestinal copper absorption
• Less potent than penicillamine, but difference is not clinically important
• Side effects: Much better tolerated - occasional gastritis, iron deficiency (chelates dietary iron); bone marrow suppression rare; neurological worsening rarely reported
• Off-label for initial treatment in the US per FDA, but accepted standard of care internationally
• Highly effective even in advanced liver fibrosis and as initial therapy in children

3. Zinc Salts

• Dose: 50 mg elemental zinc 3× daily in adults (25 mg 3× daily in children <50 kg)
• Mechanism: Induces metallothionein in gut enterocytes, which has greater affinity for copper than zinc → copper bound by metallothionein is not absorbed but lost in feces as enterocytes shed; also interferes with lipid peroxidation and enhances glutathione
• Monitoring: Target 24-hr urinary copper <75 μg/day; monitor 24-hr urinary zinc (target >2 mg/24h to confirm compliance/absorption)
• Side effects: Gastritis (common; less with zinc gluconate or acetate vs. sulfate); may cause iron deficiency; rare immediate hepatic deterioration in some patients with hepatic WD
• Preferred role: Maintenance therapy (after initial decoppering with chelator), presymptomatic patients, and patients in whom neurological WD is the primary concern
• Important limitation: Less effective than chelators for advanced hepatic WD; long-term studies show better efficacy in neurological than hepatic disease

4. Tetrathiomolybdate (Ammonium Tetrathiomolybdate / Bis-choline Tetrathiomolybdate)

• Still largely experimental/close to clinical application (WTX101/bis-choline TM under trials)
• Proposed advantage: lower risk of neurological worsening compared to penicillamine
• May be used in combination with zinc

Dietary Advice

• Eliminate copper-rich foods: organ meats, shellfish, nuts, chocolate, mushrooms
• Vegetarians need specific dietary counseling
• If drinking water has high copper (old pipes), install copper-removing filter
• Dietary restriction alone is insufficient - pharmacological treatment always required

Combination Approaches

• Chelator + zinc can be used together
• Trientine or tetrathiomolybdate + zinc for neurological disease (lower worsening risk)

When to Start Treatment

Liver Transplantation and Palliative/End-Stage Care

Indications for Liver Transplant

1. Fulminant (acute) liver failure from WD - well-established, life-saving indication; disease is uniformly fatal without transplant in this presentation; plasmapheresis may be used as a bridge to transplant or when transplant not immediately available
2. End-stage Wilsonian cirrhosis - when liver disease progresses despite good copper control (same criteria as other causes of cirrhosis)
3. NOT currently recommended for isolated neurological WD without significant liver disease - neurological symptoms can improve with pharmacological therapy

Outcomes After Transplant

• Long-term survival is excellent
• The disease does not recur in the transplanted liver (donor liver has normal ATP7B)
• Neurological and psychiatric features often improve after transplant, as the normal donor liver corrects copper metabolism and reduces the whole-body copper burden
• Wilson disease is considered cured by liver transplantation (unlike many other liver diseases which recur)

Monitoring and Long-Term Follow-Up

• CBC, renal function (urinalysis, creatinine), liver biochemical tests
• 24-hour urinary copper (main efficacy monitoring - target depends on drug used)
• Serum ceruloplasmin and copper
• Slit-lamp eye exam (to monitor KF ring response to treatment - rings fade with successful treatment)
• Side-effect monitoring as per drug used
• Neuropsychiatric assessment

Palliative Considerations

• Patients with decompensated cirrhosis not candidates for transplant - standard hepatic palliative care (ascites management, hepatic encephalopathy management, variceal management)
• Patients with severe irreversible neurological damage - multidisciplinary neurological rehabilitation, speech therapy, physiotherapy, occupational therapy, psychiatric support
• Patients declining or not eligible for transplant in fulminant liver failure - plasmapheresis/MARS (liver dialysis) as bridge measures; ultimately comfort-focused care if no curative option available
• Crucially: never stop copper-reduction treatment, as withdrawal causes rapid copper rebound and dramatic deterioration

Summary Table

Wilson Disease - Complications and Management

Complication 1: Hepatic (Liver) Complications

A. Acute Hepatitis

• Start chelation therapy (trientine preferred, or D-penicillamine + pyridoxine 25 mg/day) immediately once diagnosis is confirmed
• Doses: trientine 1-1.5 g/day divided 2-3 doses; D-penicillamine 1-1.5 g/day in adults
• Dietary copper restriction (avoid organ meats, shellfish, nuts, chocolate, mushrooms)
• Monitor: 24-hr urinary copper (target 200-500 μg/day on chelators), CBC, LFTs, renal function

B. Acute Liver Failure (Fulminant Wilson Disease)

• Acute icteric hepatitis evolving to liver failure within days
• Extreme jaundice, coagulopathy, hepatic coma, ascites
• Coombs-negative (DAT-negative) hemolytic anemia - copper released from necrotic liver destroys RBCs
• Acute renal failure (requires dialysis in most)
• Disproportionately low transaminases (<1500 U/L) despite severe disease
• Alkaline phosphatase low or normal (highly characteristic - ALP/bilirubin ratio <4 and AST/ALT >2.2 distinguishes Wilsonian ALF from other causes)
• Very high urine copper

• Liver transplantation is the definitive and life-saving treatment - these patients do NOT respond well to chelation alone
• Plasmapheresis/apheresis (albumin dialysis, MARS) as a bridge until transplant can be organized, or when transplant is not immediately available
• ICU-level supportive care: mechanical ventilation for encephalopathy, renal replacement therapy (dialysis) for acute renal failure, correction of coagulopathy
• Avoid D-penicillamine in this acute setting - it does not help and may worsen the situation
• Accounts for ~3% of all patients transplanted for acute liver failure

C. Chronic Hepatitis and Cirrhosis

• Chelation therapy (trientine or penicillamine) slows and may reverse fibrosis if started early
• Management of cirrhosis complications:
  • Ascites: salt restriction, diuretics (spironolactone ± furosemide), paracentesis for tense ascites
  • Variceal bleeding: non-selective beta-blockers for primary prophylaxis (propranolol/carvedilol); endoscopic band ligation for secondary prophylaxis; TIPS if refractory
  • Hepatic encephalopathy: lactulose, rifaximin, dietary protein adjustment
  • Splenomegaly/hypersplenism: manage cytopenias
• Liver transplantation indicated for end-stage Wilsonian cirrhosis that progresses despite good copper control - same criteria as other cirrhotic patients (MELD/Na-MELD score, life-threatening complications unresponsive to medical therapy)
• Post-transplant: disease does not recur (donor liver has normal ATP7B); neurological features often improve after transplant

D. Gallstones (Cholelithiasis)

• Treat underlying Wilson disease (reduces hemolysis)
• Symptomatic cholelithiasis: cholecystectomy (laparoscopic preferred; liver function must be assessed preoperatively if cirrhosis present)

Complication 2: Neurological Complications

• Tremor (resting and action; sometimes "wing-beating")
• Dystonia (focal or generalized)
• Chorea, choreoathetosis
• Dysarthria (slurred speech)
• Dysphagia
• Rigidity, bradykinesia (Parkinson-like)
• Ataxia, gait disturbance
• Drooling, fixed "sardonic" smile
• Seizures (minority of patients)
• MRI: T2 hyperintensity in putamen, midbrain, pons, thalamus, cerebellum; cortical atrophy

D-penicillamine causes acute worsening of neurological signs in 20-50% of patients with neurological Wilson disease. Some of these patients never recover to their pretreatment baseline. One case progressed fatally from cardiac arrhythmia.

• Adams and Victor's Principles of Neurology

• Preferred agent: Trientine (much lower risk of neurological worsening than penicillamine)
• Alternative: Tetrathiomolybdate (bis-choline tetrathiomolybdate/WTX101) - experimental but lowest neurological worsening risk
• These can be combined with zinc
• If penicillamine must be used: start at low dose and increase very slowly
• Liver transplantation improves neurological features in many patients by reducing whole-body copper load - but transplant is NOT currently recommended for isolated neurological disease without significant liver involvement (pharmacological therapy is adequate)
• Supportive therapies:
  • Physiotherapy for gait and tremor
  • Speech and language therapy for dysarthria/dysphagia
  • Occupational therapy for fine motor dysfunction
  • Antiepileptics for seizures (avoid valproate if significant liver disease)
• With effective copper-reducing therapy, most neurological features stabilize and partially or fully improve

Complication 3: Psychiatric Complications

• Personality change: irritability, anger, poor impulse control
• Depression (~30% of WD patients)
• Anxiety disorders
• Bipolar spectrum symptoms (~20%)
• Psychosis (rare but occurs)
• Suicidal ideation (5-15%)
• Cognitive dysfunction (frontosubcortical profile)
• Despite long-term treatment, ~70% of patients develop some psychiatric symptoms
• Patients are abnormally sensitive to neuroleptics (risk of severe side effects - use with caution)

• Copper-reduction therapy is the primary treatment - many psychiatric symptoms improve with effective decoppering
• Psychiatric symptoms must not be attributed to primary psychiatric illness in a young person without first ruling out Wilson disease
• Standard psychiatric treatment as adjunct: antidepressants for depression (SSRIs generally safe), mood stabilizers for bipolar features (avoid valproate if liver involvement)
• Avoid or use extreme caution with neuroleptics (increased sensitivity) - if needed, use low doses
• Psychological support, counseling, and psychiatric follow-up throughout treatment
• Wilson disease should be formally excluded in all young adults with new-onset psychiatric symptoms, especially if liver enzymes are abnormal or there is a family history

Complication 4: Coombs-Negative Hemolytic Anemia

• Treat the underlying cause: effective copper chelation reverses hemolysis
• Trientine or D-penicillamine (with pyridoxine)
• In acute massive hemolysis (fulminant presentation): supportive transfusions + urgent liver transplant evaluation
• Plasmapheresis to reduce circulating free copper as a temporizing measure in the fulminant setting
• Cholelithiasis from chronic hemolysis: see above

Complication 5: Renal Complications (Fanconi Syndrome)

• Aminoaciduria
• Phosphaturia → hypophosphatemia → rickets / osteomalacia (vitamin D-resistant)
• Glycosuria with normal blood glucose
• Uricosuria → low serum uric acid (a key diagnostic clue for Wilson disease)
• Microscopic hematuria
• Hypercalciuria → kidney stones, nephrocalcinosis
• Distal tubular dysfunction → type 1 (distal) RTA
• Decreased concentrating ability
• Renal plasma flow and GFR decrease as disease progresses (though death from extrarenal causes usually occurs before end-stage kidney failure)

• Copper chelation (trientine or penicillamine) reverses tubular dysfunction, though recovery is slow
• Phosphate replacement for hypophosphatemia/rickets
• Oral citrate or bicarbonate for renal tubular acidosis
• Increased fluid intake + urinary alkalinization for nephrolithiasis
• Monitor serum electrolytes, phosphate, uric acid, urine calcium regularly
• If trientine is used: watch for iron deficiency (trientine chelates iron) - monitor iron studies

Complication 6: Musculoskeletal Complications

• Osteoporosis and osteopenia: from chronic liver disease (reduced vitamin D activation) + renal phosphate wasting + direct copper toxicity to bone
• Rickets/osteomalacia: vitamin D-resistant, secondary to renal tubular phosphate wasting
• Spontaneous fractures
• Osteochondritis dissecans
• Chondromalacia patellae
• Degenerative arthritis: mainly large joints (knees, hips, spine) from synovial copper deposition
• Rhabdomyolysis: copper deposition in skeletal muscle (rare)
• "Osseomuscular presentation" (reported mainly from India)

• Copper chelation addresses the root cause
• Calcium and vitamin D supplementation for osteoporosis/osteomalacia
• Phosphate supplementation if renal phosphate wasting is present
• Bisphosphonates for established osteoporosis (use with caution if liver disease severe)
• Orthopedic management for osteochondritis dissecans, fractures, and degenerative joint disease
• Physiotherapy and joint protection strategies
• Bone mineral density (DEXA scan) monitoring

Complication 7: Cardiac Complications

• Echocardiographic abnormalities in up to one-third of adults
• Cardiomyopathy
• Cardiac arrhythmias (can include life-threatening ones - sudden death from cardiac involvement is rare but documented)
• Orthostatic hypotension

• Copper chelation is the primary treatment (cardiomyopathy and arrhythmias can improve or stabilize)
• ECG and echocardiogram at baseline and periodically during treatment
• Standard cardiology management for arrhythmias (anti-arrhythmics, pacemaker if indicated)
• Caution: penicillamine-induced neurological worsening has been linked to fatal cardiac arrhythmia in at least one reported case

Complication 8: Endocrine Complications

• Hypoparathyroidism: copper deposition in parathyroid glands → hypocalcemia, hyperphosphatemia
• Amenorrhea and menstrual irregularities in females (from Wilson disease itself, not just from cirrhosis)
• Testicular problems and infertility in males
• Repeated spontaneous abortions: may be the presenting sign of Wilson disease in young women
• Delayed puberty
• Pancreatitis (possible copper deposition in pancreas)

• Copper chelation addresses endocrine dysfunction at the root
• Calcium/active vitamin D (calcitriol) supplementation for hypoparathyroidism
• Hormonal assessment and replacement as needed for amenorrhea
• Fertility: Wilson disease patients can conceive successfully with treatment - never stop treatment during pregnancy (abrupt discontinuation causes sudden copper release, massive hemolysis, acute liver failure, and death)
• Pregnancy management: zinc is preferred if disease is stable; chelation with trientine or low-dose penicillamine is continued if needed; doses sometimes slightly reduced in first trimester only

Complication 9: Ocular Complications

• Kayser-Fleischer (KF) rings: green-brown copper deposits in Descemet membrane at corneal limbus; present in 98% of neurological WD and ~80% overall; first appears as a superior golden crescent, then circumferential; diagnosed by slit-lamp examination

• "Sunflower" cataracts: copper deposits in the lens producing a sunflower petal pattern (benign, do not affect vision significantly)

• KF rings and sunflower cataracts fade and disappear with successful copper-reducing treatment - their resolution is used as a marker of treatment response
• Slit-lamp examination should be performed at baseline and at follow-up visits to monitor treatment efficacy
• No specific ophthalmic treatment needed beyond copper reduction

Critical Complication: Treatment Withdrawal / Non-Compliance

"Pregnant patients must remain on medication to treat Wilson disease because discontinuation of therapy can cause sudden copper release, hemolysis, acute liver failure, and death."

• Sleisenger and Fordtran's GI and Liver Disease

• Patients who stop chelation for even a few months can develop fulminant liver failure (this is how some patients who had previously been well-controlled re-present with acute liver failure)
• Treatment is lifelong with no exceptions - this must be stressed strongly to patients and families
• If a patient cannot tolerate one agent (e.g., penicillamine side effects), switch to trientine rather than stopping treatment

Summary: Complications at a Glance